Validity of serum leukotriene B4 as a marker of decompensated liver cirrhosis in chronic HCV patients: leukotriene B4 in decompensated liver cirrhosis

MLA

Ayman El-Shayeb, et al. “Validity of Serum Leukotriene B4 as a Marker of Decompensated Liver Cirrhosis in Chronic HCV Patients: Leukotriene B4 in Decompensated Liver Cirrhosis.” Egyptian Liver Journal, vol. 11, no. 1, Oct. 2021, pp. 1–8. EBSCOhost, https://doi.org/10.1186/s43066-021-00152-1.

APA

Ayman El-Shayeb, Sawsan El-Mallah, Akram Deghady, Samar El-Hewely, & Doaa Elwazzan. (2021). Validity of serum leukotriene B4 as a marker of decompensated liver cirrhosis in chronic HCV patients: leukotriene B4 in decompensated liver cirrhosis. Egyptian Liver Journal, 11(1), 1–8. https://doi.org/10.1186/s43066-021-00152-1

Chicago

Ayman El-Shayeb, Sawsan El-Mallah, Akram Deghady, Samar El-Hewely, and Doaa Elwazzan. 2021. “Validity of Serum Leukotriene B4 as a Marker of Decompensated Liver Cirrhosis in Chronic HCV Patients: Leukotriene B4 in Decompensated Liver Cirrhosis.” Egyptian Liver Journal 11 (1): 1–8. doi:10.1186/s43066-021-00152-1.